Intellia Therapeutics, Inc. Intellectual Property Contracts & Agreements
12 Contracts & Agreements
- License Agreements (12 contracts)
- Amendment #3 to License and Collaborative Research Agreement, dated as of June 14, 2021, by and between Novartis and Intellia (Filed With SEC on June 17, 2021)
- License and Collaborative Research Agreement dated as of December 18, 2014 by and between Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on May 6, 2021)
- License Agreement dated as of July 16, 2014 by and between Registrant (as successor in interest of Intellia Therapeutics, LLC) and Caribou Biosciences, Inc (Filed With SEC on May 6, 2021)
- Agreement and Amendment to License and Collaborative Research Agreement, dated as of December 3, 2018, by and between Novartis and the Company (Filed With SEC on February 27, 2019)
- LICENSE ANDCOLLABORATION AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and INTELLIATHERAPEUTICS, INC. April 11, 2016 (Filed With SEC on May 5, 2016)
- License and Collaborative Research Agreement (Filed With SEC on May 5, 2016)
- LICENSE ANDCOLLABORATION AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and INTELLIATHERAPEUTICS, INC. April 11, 2016 (Filed With SEC on April 27, 2016)
- License and Collaborative Research Agreement (Filed With SEC on April 19, 2016)
- LICENSE ANDCOLLABORATION AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and INTELLIATHERAPEUTICS, INC. April 11, 2016 (Filed With SEC on April 12, 2016)
- ADDENDUM TO LICENSE AGREEMENT (Filed With SEC on April 11, 2016)
- AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on April 11, 2016)
- License and Collaborative Research Agreement (Filed With SEC on April 11, 2016)
